Skip to main content
PMC home page
British Heart Journal logoLink to British Heart Journal
. 1983 Dec;50(6):579–585. doi: 10.1136/hrt.50.6.579

Haemodynamic response to intravenous hydralazine in patients with pulmonary hypertension.

M D McGoon, J B Seward, R E Vlietstra, M H Choo, T P Moyer, G S Reeder
PMCID: PMC481463  PMID: 6652000

Abstract

The acute pulmonary and systemic haemodynamic response to low (0.15 mg/kg) and high (0.30 mg/kg) doses of intravenous hydralazine was evaluated in 26 consecutive patients with severe pulmonary hypertension due to cor pulmonale (nine patients), primary pulmonary hypertension (11 patients), or pulmonary embolism (six patients). Hydralazine did not cause a significant change in pulmonary arterial resistance or pressure in any group but produced a significant reduction in systemic resistance, which correlated with plasma concentration, and a significant increase in pulmonary blood flow index in all groups. Ten patients who experienced a reduction in pulmonary arterial resistance of at least 5 U X m2 after administration of hydralazine had higher initial values for pulmonary arterial resistance and systemic resistance and a lower pulmonary blood flow index than those who did not respond. Maintenance oral hydralazine treatment during nine to 36 months of follow up did not seem to affect symptoms or mortality. These results indicate that hydralazine has limited value in acutely reducing pulmonary arterial pressure or affecting clinical outcome in patients with pulmonary hypertension.

Full text

PDF
579

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Camerini F., Alberti E., Klugmann S., Salvi A. Primary pulmonary hypertension: effects of nifedipine. Br Heart J. 1980 Sep;44(3):352–356. doi: 10.1136/hrt.44.3.352. [DOI] [PMC free article] [PubMed] [Google Scholar]
  2. DRESDALE D. T., SCHULTZ M., MICHTOM R. J. Primary pulmonary hypertension. I. Clinical and hemodynamic study. Am J Med. 1951 Dec;11(6):686–705. doi: 10.1016/0002-9343(51)90020-4. [DOI] [PubMed] [Google Scholar]
  3. Danahy D. T., Tobis J. M., Aronow W. S., Chetty K., Glauser F. Effects of isosorbide dinitrate on pulmonary hypertension in chronic obstructive pulmonary disease. Clin Pharmacol Ther. 1979 May;25(5 Pt 1):541–548. doi: 10.1002/cpt1979255part1541. [DOI] [PubMed] [Google Scholar]
  4. Daoud F. S., Reeves J. T., Kelly D. B. Isoproterenol as a potential pulmonary vasodilator in primary pulmonary hypertension. Am J Cardiol. 1978 Nov;42(5):817–822. doi: 10.1016/0002-9149(78)90102-9. [DOI] [PubMed] [Google Scholar]
  5. Honey M., Cotter L., Davies N., Denison D. Clinical and haemodynamic effects of diazoxide in primary pulmonary hypertension. Thorax. 1980 Apr;35(4):269–276. doi: 10.1136/thx.35.4.269. [DOI] [PMC free article] [PubMed] [Google Scholar]
  6. LEE T. D., Jr, ROVETI G. C., ROSS R. S. The hemodynamic effects of isoproterenol on pulmonary hypertension in man. Am Heart J. 1963 Mar;65:361–367. doi: 10.1016/0002-8703(63)90011-5. [DOI] [PubMed] [Google Scholar]
  7. Landmark K., Refsum A. M., Simonsen S., Storstein O. Verapamil and pulmonary hypertension. Acta Med Scand. 1978;204(4):299–302. doi: 10.1111/j.0954-6820.1978.tb08443.x. [DOI] [PubMed] [Google Scholar]
  8. Lupi-Herrera E., Sandoval J., Seoane M., Bialostozky D. The role of hydralazine therapy for pulmonary arterial hypertension of unknown cause. Circulation. 1982 Apr;65(4):645–650. doi: 10.1161/01.cir.65.4.645. [DOI] [PubMed] [Google Scholar]
  9. Mentzer R. M., Alegre C. A., Nolan S. P. The effects of dopamine and isoproterenol on the pulmonary circulation. J Thorac Cardiovasc Surg. 1976 Jun;71(6):807–814. [PubMed] [Google Scholar]
  10. Packer M., Greenberg B., Massie B., Dash H. Deleterious effects of hydralazine in patients with pulmonary hypertension. N Engl J Med. 1982 Jun 3;306(22):1326–1331. doi: 10.1056/NEJM198206033062203. [DOI] [PubMed] [Google Scholar]
  11. Reece P. A., Cozamanis I., Zacest R. Selective high-performance liquid chromatographic assays for hydralazine and its metabolites in plasma of man. J Chromatogr. 1980 Mar 14;181(3-4):427–440. doi: 10.1016/s0378-4347(00)81145-7. [DOI] [PubMed] [Google Scholar]
  12. Rich S., Martinez J., Lam W., Rosen K. M. Captopril as treatment for patients with pulmonary hypertension. Problem of variability in assessing chronic drug treatment. Br Heart J. 1982 Sep;48(3):272–277. doi: 10.1136/hrt.48.3.272. [DOI] [PMC free article] [PubMed] [Google Scholar]
  13. Rubin L. J., Handel F., Peter R. H. The effects of oral hydralazine on right ventricular end-diastolic pressure in patients with right ventricular failure. Circulation. 1982 Jun;65(7):1369–1373. doi: 10.1161/01.cir.65.7.1369. [DOI] [PubMed] [Google Scholar]
  14. Rubin L. J., Lazar J. D. Influence of prostaglandin synthesis inhibitors on pulmonary vasodilatory effects of hydralazine in dogs with hypoxic pulmonary vasoconstriction. J Clin Invest. 1981 Jan;67(1):193–200. doi: 10.1172/JCI110012. [DOI] [PMC free article] [PubMed] [Google Scholar]
  15. Rubin L. J., Peter R. H. Hemodynamics at rest and during exercise after oral hydralazine in patients with cor pulmonale. Am J Cardiol. 1981 Jan;47(1):116–122. doi: 10.1016/0002-9149(81)90299-x. [DOI] [PubMed] [Google Scholar]
  16. Rubin L. J., Peter R. H. Oral hydralazine therapy for primary pulmonary hypertension. N Engl J Med. 1980 Jan 10;302(2):69–73. doi: 10.1056/NEJM198001103020201. [DOI] [PubMed] [Google Scholar]
  17. Ruskin J. N., Hutter A. M., Jr Primary pulmonary hypertension treated with oral phentolamine. Ann Intern Med. 1979 May;90(5):772–774. doi: 10.7326/0003-4819-90-5-772. [DOI] [PubMed] [Google Scholar]
  18. Satyanarayana Rao B. N., Moller J. H., Edwards J. E. Primary pulmonary hypertension in a child. Response to pharmacologic agents. Circulation. 1969 Oct;40(4):583–587. doi: 10.1161/01.cir.40.4.583. [DOI] [PubMed] [Google Scholar]
  19. Shettigar U. R., Hultgren H. N., Specter M., Martin R., Davies D. H. Primary pulmonary hypertension favorable effect of isoproterenol. N Engl J Med. 1976 Dec 16;295(25):1414–1415. doi: 10.1056/NEJM197612162952506. [DOI] [PubMed] [Google Scholar]
  20. Szczeklik J., Dubiel J. S., Mysik M., Pyzik Z., Krol R., Horzela T. Effects of prostaglandin E1 on pulmonary circulation in patients with pulmonary hypertension. Br Heart J. 1978 Dec;40(12):1397–1401. doi: 10.1136/hrt.40.12.1397. [DOI] [PMC free article] [PubMed] [Google Scholar]
  21. Wang S. W., Pohl J. E., Rowlands D. J., Wade E. G. Diazoxide in treatment of primary pulmonary hypertension. Br Heart J. 1978 May;40(5):572–574. doi: 10.1136/hrt.40.5.572. [DOI] [PMC free article] [PubMed] [Google Scholar]

Articles from British Heart Journal are provided here courtesy of BMJ Publishing Group

RESOURCES